About

We Combine In-vitro-Grown Human Organoids with
Deep-Learning AI Analysis Technology.

About

Vision & Merit

Vision

  • Integrated Organoid Ecosystem

    ORG Co. operates four main business areas: cell culture reagents, human organoids, organoid AI analysis, and advanced regenerative medicine.

  • New Global Standard for
    Alternatives to Animal Testing

    We develop and supply high-quality, standardized human organoids for modeling organ development and chronic diseases and assessing therapeutic efficacy.

  • From Lab to Bedside

    ORG Co. is opening new possibilities for regenerative therapies and treatments for rare diseases, contributing directly to the improvement of human health.

Merit

  • Source Technology

    Proprietary Technology and Expertise

    ORG Co. possesses proprietary technologies and expertise in the generation of human induced pluripotent stem cells, advanced cardiac and skin organoid differentiation, the recapitulation of developmental processes, and the production of human cell-derived extracellular matrix (ECM).

  • Convergence Solution

    Integrated Business Models

    ORG Co. has built an integrated business portfolio spanning organoid production and analysis, AI-based software, and therapeutic development, with each business area complementing the others to create cross-business synergies

  • Therapeutic Pipeline

    Innovative Therapeutic Pipeline

    We are actively developing human cardiac organoid based regeneration therapeutics that can drive substantial milestone revenue and corporate value growth.

  • Regulatory Adaptability

    Global Regulatory Adaptability

    We proactively respond to changes in the global regulatory environment. In line with the Animal Testing Alternatives Act (NAMs), we are developing organoid based technologies that meet international standards, leading a paradigm shift in R&D toward models that can fully replace animal testing.

Future Growth Roadmap

This is a business journey to secure a leading position in the global market by combining ORG Co., Ltd.'s unrivaled organoid technology with an AI platform.